• Cindy S Tofthagen, Susan C McMillan, and Kevin E Kip.
• College of Nursing, University of South Florida, Tampa, Florida 33612, USA. ctofthag@health.usf.edu
• Cancer Nurs. 2011 Jul 1; 34 (4): E10-20.

BackgroundChemotherapy-induced peripheral neuropathy (CIPN) can be a debilitating and dose-limiting adverse effect of chemotherapy. Comprehensive self-report tools for CIPN are needed for research and clinical practice.ObjectiveThe purpose of this psychometric study was to describe the development and evaluate the reliability and validity of a new self-report tool designed to measure CIPN, the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT).MethodsOne hundred sixty-seven patients receiving outpatient chemotherapy with paclitaxel, docetaxel, cisplatin, or oxaliplatin completed the CIPNAT. Content validity, convergent validity, discriminant validity, test-retest reliability, and internal consistency reliability were assessed.ResultsContent validity index was very acceptable at 0.95. Convergent validity data were provided by correlation with a measure of the same concept (r = 0.83, P < .001), and differences between contrasting groups (t = 7.66, P < .001) provided evidence of discriminant validity. High test-retest correlations (r = 0.92, P < .001), Cronbach α (α = .95), and significant item-to-total correlations ranging from 0.38 to 0.70 provided evidence of reliability.ConclusionsResults provide evidence of the validity and reliability of the CIPNAT, which can be used for comprehensive assessment of CIPN.Implications For PracticeUse of the CIPNAT in research may lead to a better understanding of CIPN and guide nurses in developing and testing of interventions to relieve suffering and enhance quality of life for patients with CIPN.

19 keywords...

hide…